Abeona Therapeutics (NASDAQ: ABEO) reported Q3 EPS of ($0.08), $0.11 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $184 thousand versus the consensus estimate of $240 thousand.

Cash, cash equivalents and marketable securities as of September 30, 2016 were $31.2 million, compared to $34.3 million as of June 30, 2016. Net cash used in operating activities in the Nine Months Ended September 30, 2016 was $9.6 million as compared to $7.5 million in the same period in 2015, an increase of $2.1 million.

For earnings history and earnings-related data on Abeona Therapeutics (ABEO) click here.